Frankfurt - Delayed Quote EUR

AlzeCure Pharma AB (publ) (AC6.F)

0.1755

-0.0015

(-0.85%)

At close: May 2 at 8:12:33 AM GMT+2

Notice to Annual General Meeting in AlzeCure Pharma AB

STOCKHOLM, SE / ACCESS Newswire / April 9, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - The shareholders of AlzeCure Pharma AB, reg. no. 559094-8302 (the "Company") are hereby invited to attend the annual general meeting to be held on Wednesday ...

ACCESS Newswire 24 days ago

AC6.F
-0.85%

ALZCUR.ST
+3.38%
New Data Bolstering the Anti-inflammatory Effect of NeuroRestore ACD856 Presented at Alzheimer's Conference

STOCKHOLM, SE / ACCESS Newswire / April 7, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's disease and pain, announced today ...

ACCESS Newswire 26 days ago

AC6.F
-0.85%

ALZCUR.ST
+3.38%
AlzeCure Pharma publishes its Annual Report for 2024

STOCKHOLM, SE / ACCESS Newswire / April 3, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's ...

ACCESS Newswire 30 days ago

AC6.F
-0.85%

ALZCUR.ST
+3.38%
New Scientific Article in Nature Linking the Potential use of NeuroRestore ACD856 for the Treament of Obesity

STOCKHOLM, SE / ACCESS Newswire / April 2, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's ...

ACCESS Newswire last month

ALZCUR.ST
+3.38%

AC6.F
-0.85%
AlzeCure Pharma to present at Redeye Theme: Alzheimer & Parkinsons on April 8

STOCKHOLM, SE / ACCESS Newswire / April 1, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's ...

ACCESS Newswire last month

ALZCUR.ST
+3.38%

AC6.F
-0.85%
AlzeCure Publishes its Year-End Report for January - December 2024

STOCKHOLM, SWEDEN / ACCESS Newswire / February 27, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR) today announced that its Year-end report for the period January - December 2024 is now available on the company's ...

ACCESS Newswire 2 months ago

AC6.F
-0.85%

ALZCUR.ST
+3.38%
New Article Showing the Unique Mechanism of Action Behind Alzstatin as an Alzheimer's Treatment

STOCKHOLM, SWEDEN / ACCESS Newswire / February 24, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR) ), a pharmaceutical company that develops candidate drugs for CNS diseases, focusing on Alzheimer's disease and ...

ACCESS Newswire 2 months ago

AC6.F
-0.85%

ALZCUR.ST
+3.38%
AlzeCure Receives EU Grant for Phase 2 Clinical Trial of NeuroRestore ACD856 for Alzheimer's Disease

AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's disease and pain, today announced that its project ...

ACCESS Newswire 2 months ago

ALZCUR.ST
+3.38%

AC6.F
-0.85%
AlzeCure Receives Abstract Acceptance at Alzheimer’s Congress AD/PD 2025 on NeuroRestore ACD856

STOCKHOLM, SE / ACCESSWIRE / January 21, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's ...

ACCESS Newswire 3 months ago

AC6.F
-0.85%

ALZCUR.ST
+3.38%
AlzeCure to Present at the Pharma Outsourcing Conference in Stockholm

STOCKHOLM, SWEDEN / ACCESSWIRE / November 27, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops small molecule drugs for diseases affecting the nervous system, focusing on ...

ACCESS Newswire 5 months ago

AC6.F
-0.85%

ALZCUR.ST
+3.38%
AlzeCure Pharma to Present at Redeye Life Science Day on December 3

STOCKHOLM, SWEDEN / ACCESSWIRE / November 26, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's ...

ACCESS Newswire 5 months ago

ALZCUR.ST
+3.38%

AC6.F
-0.85%
AlzeCure Pharma to Present at Stora Aktiedagarna in Stockholm

STOCKHOLM, SWEDEN / ACCESSWIRE / November 20, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's ...

ACCESS Newswire 5 months ago

ALZCUR.ST
+3.38%

AC6.F
-0.85%
AlzeCure Publishes its Interim Report for January – September 2024

STOCKHOLM, SE / ACCESSWIRE / November 11, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR) today announced that its interim report for the period January - September 2024 is now available on the company's website: ...

ACCESS Newswire 5 months ago

AC6.F
-0.85%

ALZCUR.ST
+3.38%
AlzeCure Presents New Anti-Inflammatory Data with NeuroRestore ACD856 at the Alzheimer's Conference CTAD

STOCKHOLM, SE / ACCESSWIRE / October 30, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's ...

ACCESS Newswire 5 months ago

AC6.F
-0.85%

ALZCUR.ST
+3.38%
AlzeCure Presents New Positive Data for the TrkA-NAM Pain Project Against Osteoarthritis

STOCKHOLM, SE / ACCESSWIRE / October 28, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for CNS diseases, focusing on Alzheimer's disease and pain, today ...

ACCESS Newswire 6 months ago

AC6.F
-0.85%

ALZCUR.ST
+3.38%
AlzeCure to Present at the International Partnering Conference Bioscience 2024 on November 7

STOCKHOLM, SE / ACCESSWIRE / October 24, 2024 /AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's ...

ACCESS Newswire 6 months ago

AC6.F
-0.85%

ALZCUR.ST
+3.38%
AlzeCure Pharma's CEO Martin Jönsson to present at Redeye's Neurology Day

STOCKHOLM, SE / ACCESSWIRE / October 17, 2024 / AlzeCure Pharma (STO:ALZCUR) (FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's ...

ACCESS Newswire 6 months ago

ALZCUR.ST
+3.38%

AC6.F
-0.85%
AlzeCure Pharma Broadcasts Live Event About the Phase II Candidate ACD440 Against Neuropathic Pain

STOCKHOLM, SE / ACCESSWIRE / October 10, 2024 / AlzeCure Pharma (STO:ALZCUR) (FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's ...

ACCESS Newswire 6 months ago

ALZCUR.ST
+3.38%

AC6.F
-0.85%
AlzeCure's Abstract on ACD856's Anti-inflammatory Effects to be Presented at a Leading Alzheimer's Conference

STOCKHOLM, SWEDEN / ACCESSWIRE / October 1, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's ...

ACCESS Newswire 6 months ago

ALZCUR.ST
+3.38%

AC6.F
-0.85%
AlzeCure Publishes its Interim Report for January – June 2024

STOCKHOLM, SE / ACCESSWIRE / August 26, 2024 / AlzeCure Pharma (STO:ALZCUR) (FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR) today announced that its interim report for the period January - June 2024 is now available on the company's website: ...

ACCESS Newswire 8 months ago

ALZCUR.ST
+3.38%

AC6.F
-0.85%

Performance Overview

Return	AC6.F	OMX Stockholm 30 Index (^OMX)
YTD	+183.98%	-0.83%
1-Year	+45.64%	-2.48%
3-Year	-16.93%	+21.88%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

AlzeCure Pharma AB (publ) (AC6.F)

Notice to Annual General Meeting in AlzeCure Pharma AB

New Data Bolstering the Anti-inflammatory Effect of NeuroRestore ACD856 Presented at Alzheimer's Conference

AlzeCure Pharma publishes its Annual Report for 2024

New Scientific Article in Nature Linking the Potential use of NeuroRestore ACD856 for the Treament of Obesity

AlzeCure Pharma to present at Redeye Theme: Alzheimer & Parkinsons on April 8

AlzeCure Publishes its Year-End Report for January - December 2024

New Article Showing the Unique Mechanism of Action Behind Alzstatin as an Alzheimer's Treatment

AlzeCure Receives EU Grant for Phase 2 Clinical Trial of NeuroRestore ACD856 for Alzheimer's Disease

AlzeCure Receives Abstract Acceptance at Alzheimer’s Congress AD/PD 2025 on NeuroRestore ACD856

AlzeCure to Present at the Pharma Outsourcing Conference in Stockholm

AlzeCure Pharma to Present at Redeye Life Science Day on December 3

AlzeCure Pharma to Present at Stora Aktiedagarna in Stockholm

AlzeCure Publishes its Interim Report for January – September 2024

AlzeCure Presents New Anti-Inflammatory Data with NeuroRestore ACD856 at the Alzheimer's Conference CTAD

AlzeCure Presents New Positive Data for the TrkA-NAM Pain Project Against Osteoarthritis

AlzeCure to Present at the International Partnering Conference Bioscience 2024 on November 7

AlzeCure Pharma's CEO Martin Jönsson to present at Redeye's Neurology Day

AlzeCure Pharma Broadcasts Live Event About the Phase II Candidate ACD440 Against Neuropathic Pain

AlzeCure's Abstract on ACD856's Anti-inflammatory Effects to be Presented at a Leading Alzheimer's Conference

AlzeCure Publishes its Interim Report for January – June 2024

Performance Overview